Mathai Mammen Headlines LifeSciences BC's Breakfast Speaking Series - Keening Your EdgeSeptember 17, 2008With Dr. Mathai Mammen of the Bay Area's Theravance And local community members Dr. Michael Hayden of the BC Clinical Genomics Network and Bruce Schmidt of Genome BC  Mathai Mammen shares his expertise with LifeSciences BC members LifeSciences BC was pleased to welcome Bruce Schmidt, Director of Corporate Development at Genome BC, and Dr. Michael Hayden, Principle Investigator, British Columbia Clinical Genomics Network, who represented our local community at this Breakfast Speaking Series. Research is the foundation of our industry, and many members took this opportunity to learn more and appreciate the role of organizations like these that are formed specifically to support that research.  Bruce Schmidt  Michael Hayden Dr. Mathai Mammen of Theravance was our featured speaker for this Breakfast Speaking Series. As a Harvard- and MIT-educated scientific founder and head of research at Theravance, Mammen shared his story of building this billion-dollar Bay Area company, right from getting it off the ground to verging on market approval. Mammen shared how he’s honed Theravance’s unique edge of multivalent drug design, nurturing it every day and leveraging it to successfully raise money; develop strategic partnerships with the likes of GSK, Astellas and AstraZeneca; create a differentiating culture where he can hire the best in the industry; build a robust pipeline of seven products in the clinic, and ultimately deal with the FDA for the pending approval of their lead product.  Attendees networking over breakfast Bio Mathai Mammen, M.D., Ph.D. Mathai Mammen, M.D., Ph.D., co-founded Theravance in 1996. He was promoted to Senior Vice President, Research, in January 2008. He has served in various positions in both the Medicinal Chemistry Department and the Molecular and Cellular Biology Department, most recently as Vice President, Molecular and Cellular Biology, responsible for all molecular pharmacology, molecular biology, cell biology, microbiology and enzymology activities in support of projects in both Research and Development. Dr. Mammen obtained his M.D. from Harvard Medical School/Massachusetts Institute of Technology, and his Ph.D. in Physical Organic Chemistry from Harvard University's Department of Chemistry. Dr. Mammen obtained his Bachelor's Degree in Chemistry from Dalhousie University in Halifax, Nova Scotia. Michael Hayden, MD, PhD Michael Hayden has led and managed highly successful scientific networks, including the Canadian Genetic Diseases Network that was recognized as a model network by the NCE program, and others involving successful collaboration with industry. He has co-founded three pharmaceutical companies: Xenon Pharmaceuticals, Aspreva Pharmaceuticals Inc., and Neurovir, and currently serves as Chief Scientific Officer for Xenon Pharmaceuticals. As Director and Senior Scientist of the Centre for Molecular Medicine and Therapeutics, Child & Family Research Institute, Dr. Hayden has led a highly successful, international and self-sustaining scientific enterprise with a track record for generating support for research. He is currently Professor of Medical Genetics at the University of BC and is author of over 400 peer-reviewed publications. He holds a Tier 1 Canada Research Chair and is a University Killam Professor. Bruce Schmidt A founding director of Genome British Columbia, Bruce Schmidt focuses on institutional relationships, business development, public affairs, and research funding. Mr. Schmidt has served as a director for a number of high tech and biotech companies in Canada and is a founding Director of the TSX Venture Exchange Listed Company Association. He has also served as a Reviewer for the Network of Centers of Excellence and an industry member of the New Economy Group of the British Columbia Securities Commission. Currently, he is a Director of Biophage Pharma Inc. in Montreal and Duft Biotech Capital Inc. in Vancouver. He is past Director of the Canadian Healthcare Licensing Association and past Chairman of the British Columbia Biotechnology Alliance. LifeSciences BC's Breakfast Speaking Series is generously sponsored by:   |
 Suite 900 - 1188 West Georgia St.
Vancouver, BC V6E 4A2 |